URSAPHARM
URSAPHARM is a german ophthalmic pharmaceutical manufacturer with international distribution.
Analyst Perspective
URSAPHARM Arzneimittel GmbH is a German family-owned pharmaceutical manufacturer focused on ophthalmology, alongside medicinal products, medical devices and food supplements. The company operates from Germany and serves multiple international markets through local country domains, subsidiaries and distribution channels. Its core business is the development, manufacture and sale of healthcare products rather than software, advertising technology or media services. URSAPHARM generates revenue from product sales into healthcare and pharmacy channels. Its digital assets support education and brand communication, including a consumer-facing eye-health magazine integrated into its website, but these properties function as demand support rather than standalone monetisation businesses. Its direct customers are healthcare-system intermediaries and professional channels, while end users include patients and consumers purchasing ophthalmic and related health products.
Analyst Signal Briefing
Archived (As of: 3 Jul 2026)No strategic news signals detected in the last 90 days.
Explorer Tier
Start exploring for free
Start with public company intelligence. Save companies, build your first watchlist, and unlock deeper strategic insights when you are ready.
- View public Company Profiles
- Save/watch companies
- Build your first Watchlist
- Access additional market signals
Key insights about URSAPHARM
Category Differentiation
URSAPHARM is a pharmaceutical and medical products manufacturer, not an adtech, martech or healthcare software vendor. Its digital magazine is a branded education property, not a standalone publisher monetised through advertising.
URSAPHARM: About
URSAPHARM creates value by developing, manufacturing and commercialising pharmaceutical and related healthcare products, with a strong concentration in ophthalmology. It monetises through physical product sales distributed via pharmacies, healthcare providers and country-level commercial channels. Its owned digital content supports awareness, education and downstream product demand, reinforcing core product sales rather than operating as a separate digital business line.
How URSAPHARM Works & Monetises
Business model analysis and core revenue streams
URSAPHARM monetises primarily through one-off sales of pharmaceutical products, medical devices and food supplements. Commercial revenue flows through pharmacy, healthcare and distribution channels across Germany and other international markets. Its website and educational content act as marketing and patient-information tools that support product demand and brand equity rather than subscription, advertising or SaaS revenue.
Revenue Channels
Products & Services in Categories
Verified structural categorizations from the graph
Media Channel
Technology
Recent Signals (URSAPHARM)
Where to Watch and Listen Bundesliga 2026/27
The 2026/27 Bundesliga season begins on 28 August 2026 with Bayern Munich vs. VfB Stuttgart (20:30) available free on Sat.1 and also broadcast on Sky. Live rights are split across multiple broadcasters and streamers: Sky retains the largest share (covering Friday 20:30 matches, most Saturday single matches and the Saturday 18:30 top match), DAZN carries Sunday fixtures and the exclusive Saturday 15:30 conference, Sat.1 offers selected free-to-air matches and highlights, and RTL will for the first time broadcast up to ten free-to-air Bundesliga matches (also on RTL+). Audio coverage is provided by ARD with expanded embedding on external tickers (kicker, RND, Bundesliga site). The fragmentation creates more touchpoints and packaging/monetization opportunities for advertisers and sponsors, while several clubs announced new sponsors (e.g., XPeng with Mainz 05, Captain Morgan with Borussia Dortmund).
Read original sourceXPeng Becomes Mobility Partner of Mainz 05
MEEDIA reports that Chinese automaker XPeng has been announced as the mobility partner of Bundesliga club 1. FSV Mainz 05. The article, published August 20, 2026 by Frank Puscher, also summarizes other sponsorship moves ahead of the 2026/27 season: Original Wagner (Wagner Pizza) partners with SV Elversberg; Lexware replaces Jobrad as SC Freiburg's jersey partner; Beumer Group becomes Schalke 04's main sponsor; and Hedenkamp will be SC Paderborn's new shirt sponsor after Four 20 Pharma ended its partnership. The piece notes the exit of Volkswagen, Congstar and MHP from top-tier jersey sponsorship lists following relegations and includes a sourced table of estimated annual jersey sponsorship amounts for Bundesliga clubs.
Read original sourceURSAPHARM: Frequently Asked Questions
What is URSAPHARM?
URSAPHARM is a German family-owned pharmaceutical manufacturer specialising in ophthalmology, medical devices and related health products.
Who uses URSAPHARM?
Its products are bought through pharmacies, distributors and healthcare providers, and ultimately used by patients and consumers, especially in eye care.
How does URSAPHARM make money?
It makes money by selling pharmaceutical products, medical devices and food supplements through healthcare and pharmacy distribution channels.
Company Facts
- Founded
- 1974
- Headquarters
- Germany
- Core Segment
- Other / Non-Digital Advertising Relevant
- Company Size
- 501–1,000
- Official Link
- ursapharm.de